Julie Veriepe-Salerno | Immunobiologie

Posted on by ScienceFather

Dr Julie Veriepe-Salerno : Leading Researcher in Immunobiologie

Dr Julie Veriepe-Salerno at Université de Geneve, Switzerland.

Congratulations,Dr Julie Veriepe-Salerno on winning the esteemed Young Scientist award from Young scientist Awards! Your dedication, innovative research, and scholarly contributions have truly made a significant impact in your field. Your commitment to advancing knowledge and pushing the boundaries of research is commendable. Here’s to your continued success in shaping the future of academia and making invaluable contributions to your field. Well done

 

Professional Profile

 

Education:

  • 2007: Veterinary studies, Lycée Fénelon, Paris, France 🐾
  • 2010: Bachelor in Cellular Biology and Physiology, Strasbourg, France 🧫
  • 2011: Master in Cellular and Integrated Neurosciences, Montréal, Canada 🧠
  • 2012: Master in Cellular and Integrated Neurosciences, Strasbourg, France 🎓
  • 2016: PhD in Cellular Biology and Pathology, specialized in the nervous system
    • Director: Dr. Parker, University of Montreal, Canada 🧬
  • 2018: Entrepreneurship course at EPFL, Lausanne, Switzerland. 🚀

Research:

  • During PhD: Used C. elegans models to understand the role of the immune system in a neurodegenerative disease and to find new active molecules.
  • Postdoc: Focused on hematological cancers, investigating the role of MALT1 using different models (C. elegans, mice, and cell culture).
  • Current Position: Interested in hematological cancers such as multiple myeloma. Searching for new therapeutics using cell lines, 3D coculture, C. elegans, murine in vivo studies, and human biopsies.

Publications & Communications:

  1. Vérièpe-Salerno J*, Freitas Misakyan MF*, Ferro A, Cuendet M. A new therapeutic compound for multiple myeloma. In preparation.
  2. Vérièpe-Salerno J, Podavini S, Long MJC, Kolotuev I, Cuendet M, Thome M. MALT1 shortens lifespan by inhibiting autophagy in the intestine of C. elegans. Autophagy reports. 2023
  3. Gan-Or Z, Bouslam N, Birouk N, Lissouba A, Chambers DB, Vérièpe J, Androschuck A, Laurent SB, Rochefort D, Spiegelman D, Dionne-Laporte A, Szuto A, Liao M, Figlewicz DA, Bouhouche A, Benomar A, Yahyaoui M, Ouazzani R, Yoon G, Dupré N, Suchowersky O, Bolduc FV, Parker JA, Dion PA, Drapeau P, Rouleau GA, Bencheikh BO. Mutations in CAPN1 Cause Autosomal-Recessive Hereditary Spastic Paraplegia. The American Journal of Human Genetics. 2016
  4. Vérièpe J, Fossouo L, Parker A. Neurodegeneration in C. elegans models of ALS requires TIR-1/Sarm1 immune pathway activation in neurons. Nature Communications. 2015.
  5. Aggad D, Vérièpe J, Tauffenberger A, Parker A. TDP-43 Toxicity Proceeds via Calcium Dysregulation and Necrosis in Aging C. elegans Motor Neurons. Journal of Neuroscience. 2014.
  6. Laux-Biehlmann A, Chung H, Mouheiche J, Vérièpe J, Delalande F, Lamshöft M, Welters ID, Soldevila S, Bazin H, Lamarque L, Van Dorsselaer A, Poisbeau P, Schneider F, Goumon Y, Garnero P. Endogenous morphine-6-glucuronide is present in the plasma of patients: Validation of a specific anti-morphine-6-glucuronide antibody for clinical and basic research. BioFactors. 2014.
  7. Laux-Biehlmann A, Mouheiche J, Vérièpe J, Goumon Y. Endogenous morphine and its metabolites in mammals: history, synthesis, localization and perspectives. Neuroscience. 2013.

Last attended conferences:

  • 2022 C. elegans international congress – Vienna, Austria – Oral presentation 🎙️
  • 2022 11th Swiss Cancer Center Leman – Geneva – Oral presentation 📊
  • 2022 Swiss 3Rs Day Conference – Bern – Invited for an oral presentation 🇨🇭
  • 2023 ISREC-SCCL Symposium 2023, Horizon Biology & Precision Oncology – Poster presentation 📝